Home » Consulting Services » Drug Compendia and EMR »

Drug Compendia and EMR

PHSL understands the importance of having your drug product properly listed in the drug compendia for physician prescribing, pharmacy product selection and by payers for claims adjudication. PHSL has a strong knowledge of the main drug compendia providers: Medi-Span, First Databank, Cerner Multum, Gold Standard, and Red Book. We assist clients with drug compendia research, completion of compendia forms, and submission of forms and supporting communications to each compendia provider. PHSL also monitors listings in the compendia and EMR systems to ensure there are no inconsistencies with how your product appears. Let PHSL assist your organization in understanding drug compendia market dynamics and appropriate listings of your products within the various compendia.

View our case studies related to drug compendia and EMR systems:

Assistance Listing Devices in the Drug Compendia

Conversion from Multiple Platforms to a Single New Claims Processing System: GCN to GPI Crosswalk

Correcting Compendia for Better Differentiation of Products

Drug Compendia Assistance for OTC Products

Drug Compendia Product Submission

Listing a BLA-Approved Product Competing with Devices in Drug Compendia

Manufacturer Sought Insight on Inner-Pack NDC Compendia Listing

Manufacturer Sought Insight on Package Size Compendia Listing Issue

Monitoring Drug Compendia Listings of Competition

Post-Launch Drug Compendia Review

Post-Merger Product Review in Drug Compendia

Research Updates Brand Designation in Drug Databases

Therapeutic Classification in Drug Compendia at Product Launch

Understanding EHR Systems and Drug Compendia Databases

May 2023 Question of the Month

Which type of project(s) could you or your organization most benefit from in 2023?

Future forecast: 0%

Competitor comparison: 20%

Contract variance analysis: 20%

Historical trend analysis: 20%

Legislative/regulatory impact: 0%

Procurement cost/savings: 20%

Stakeholder program impact: 20%

April 2023 Question of the Month

In July 2022, the FDA proposed expanding the NDC to a uniform 12 numeric digit format to accommodate future needs when all options using the current formats have been exhausted. Alternative options shared by the industry have asked the FDA to consider retaining the current NDC formats and allow the use of alpha characters when all numeric options have been exhausted.

Which of the following transition types is your organization prepared for in the next 5 years?

Make the transition to alphanumeric using the current NDC formats: 70%

Make the transition to the 12-digit numeric format: 20%

Make the transition to neither option: 10%

Make the transition to either option: 0%

March 2023 Question of the Month

What information would you most like to gain from an Online Listening Assessment for a particular drug therapy or device? (Multiple selections allowed)

Prescribing & Dispensing Concerns: 25%

Competitor Comparisons: 25%

Prescribing Information Alignment: 17%

Coverage & Reimbursement: 17%

Patient Affordability: 8%

Misinformation: 8%

Disease State Concerns: 0%